Sign in
Taking people in United StatesPhase 1

Insulin nasal spray tested for safety in people with spinal cord injury

Tests whether insulin nasal spray is safe for adults with spinal cord injury.

Key facts

Who runs it
HealthPartners Institute
Where
Saint Paul, United StatesSee the site
Trial code
Registry title
Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury
Status
Recruiting
Phase
Phase 1
People taking part
12 people, planned
Started
20 Feb 2026
Expected to end
Jan 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Regular Insulin
  • 0.9 % Normal Saline
Record updated
15 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had a spinal cord injury at least 4 months ago. It tests whether insulin given as a nasal spray is safe, compared with a placebo (inactive) spray.

Age
18 to 84 years (the criteria say ≥18 and <85 years)
Sex
All sexes
Disease stage
Traumatic or non-traumatic spinal cord injury, ASIA rating A, B, C or D, complete or incomplete. The injury must have happened at least 4 months before the first study visit.
Earlier treatment
A stable set of medicines for at least 30 days before the first study visit. People taking insulin for Type I or Type II diabetes cannot join.
Biomarker or test result
Women must have a negative pregnancy test at screening and treatment visits, unless at least 2 years past menopause or surgically sterile.

Main reasons for not taking part

  • Needing a ventilator or having an open tracheostomy (breathing hole in the neck)
  • Repeated autonomic dysreflexia (sudden high blood pressure episodes) in the past 6 months
  • Chronic sinusitis, past nose or throat surgery, or a severely bent nasal septum
  • Allergy or serious reaction to insulin
  • Being pregnant or breastfeeding

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Subject is ≥18 and <85 years of age
  • Subject has sustained a traumatic or non-traumatic spinal cord injury with American Spinal Injury Association (ASIA) rating A, B, C or D, complete or incomplete
  • Subject sustained spinal cord injury at least 4 months before baseline visit
  • Female subjects must have either: (1) a negative pregnancy test at the screening and treatment visits OR (2) be at least 2 years post-menopausal / surgically sterile
  • The subject must be proficient in English in order to comply with instructions and measures for the study
  • Subject is able to prepare and administer the study drug as outlined in the protocol or has a carer who is available to do so for the duration of the study
  • Subject can provide written informed consent
  • Subject has been on a stable regimen of medications for at least 30 days from baseline visit

Who cannot take part

  • Subject has medical history and/or clinically determined disorders: chronic sinusitis, previous nasal and/or oto-pharyngeal surgery and severe deviated septum and/or other anomalies
  • Subject has recent history (within past 6 months) of recurrent autonomic dysreflexia, defined as a sudden rise in systolic BP greater than 20 mmHg or diastolic BP greater than 10 mmHg without rise in heart rate and accompanied by symptoms such as headache, facial flushing, sweating, nasal congestion, or blurry vision
  • Subject has history of any of the following: active and significant central nervous system, psychiatric illness, pulmonary, or cardiovascular disorders or any other clinically relevant abnormality that inclusion would pose a safety risk to the subject as determined by investigator
  • Subject has a history of allergy, hypersensitivity, or other significant adverse reaction to insulin
  • Subject is taking insulin for Type I or Type II diabetes
  • Subject is dependent on a ventilator or has a patent tracheostomy site
  • Subject has participated in a clinical trial investigation within 3 months of this study
  • Subject is pregnant or breast feeding
  • Any other clinically relevant finding that would pose a safety risk to the subject as determined by the investigator

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 84 years old?

This trial is currently available in United States.

  • HealthPartners Neuroscience CenterSaint Paul, United StatesContact: Meghan E O'Brien, MPHTaking people

About the trial

What the trial wants to find out

The purpose of this study is to find out whether insulin, a drug approved by the FDA for the treatment of diabetes mellitus, is safe when administered as a nasal spray (intranasally) to people who have experienced a spinal cord injury. While insulin nasal spray has been shown to be safe in many patient populations, it has not yet been studied in people with spinal cord injury. This study would be the first step to developing insulin nasal spray as a treatment for spinal cord injury in the future.

Read full original descriptionShow less

This study is recruiting up to 12 individuals who have experienced a spinal cord injury at least 4 months ago to administer either 76 IU insulin nasal spray or a placebo (inactive nasal spray) at home every day for up to 24 days. Participants will be asked questions about their health and symptoms related their spinal cord injury, and will have their blood collected throughout the study. Participants who are unable to administer the medication independently must have a study partner in order to participate.

The 2 groups in the trial

  • Intranasal InsulinTreatment being tested

    Regular Insulin (Novolin-R) 76 international units per day administered as 38 IU in one nostril twice daily (alternating nostrils) for 21+/-3 days

    Treatment: Regular Insulin

  • PlaceboPlacebo, for comparison

    0.9% sodium chloride in one nostril twice daily (alternating nostrils) for 21+/- days

    Treatment: 0.9 % Normal Saline

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury
Plain-language title
Insulin nasal spray tested for safety in people with spinal cord injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07384052, who can take part
Record updated
15 September 2026